Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance
CARLSMED, INC. (CARL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Carlsmed ® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, CALIFORNIA, AUGUST 5, 2026 (G
How this was made
The 30-second read
Why it matters
Traders can update valuation models using the raised FY revenue range and reassess the probability-weighted contribution from the Oct 1, 2026 CMS ruling for inpatient aprevo lumbar procedures.
Market read
The combination of a guidance raise, strong YoY growth, and a dated reimbursement catalyst is a direct input to near-term estimate revisions and positioning.
What to watch
CMS IPPS impact is dated to Oct 1, 2026; near-term results may still depend on surgeon adoption pace and commercialization ramp for cervical procedures.
Background
This is an SEC 8-K (Item 2.02) with a press release covering Q2 2026 results, business highlights, and updated FY 2026 revenue guidance, plus commentary on CMS reimbursement changes.
Ticker impact
Carlsmed reported Q2 2026 revenue of $18.9M (+57% YoY) and raised full-year 2026 guidance to $74M-$78M.
Moderately positive bias for the next few sessions as traders reprice FY revenue expectations and CMS-driven reimbursement optionality.
The filing is a primary earnings/guidance disclosure with specific financials (revenue, gross margin) and a higher FY range, plus a dated CMS reimbursement effective Oct 1, 2026.
Market effects
Reinforces demand and reimbursement tailwinds for AI-enabled surgical platforms, potentially improving risk appetite for similar medtech names.
Limited, company-specific US medtech read-through.
Low, primarily US reimbursement and Medicare IPPS related.
Counterpoint
Despite revenue growth, operating expenses rose sharply and the company still reported a large net loss, so upside may be capped if profitability milestones slip.
Key entities
- companyCarlsmed, Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and raising full-year 2026 revenue guidance.
- regulatorCMS IPPS (FY 2027) ruling
Finalized IPPS rule adding MS-DRG codes and favorable reimbursement for inpatient aprevo lumbar procedures effective Oct 1, 2026.
